HopeStage
Back to all studies
CompletedNCT00340379

Ziprasidone or combined antidepressant and antipsychotic treatment for psychotic depression

About this titleRead the official source — NCT00340379
Medication studyAges 18–75Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 75 years.

Listed locations
Los Angeles and 2 more locationsSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2003
Recruitment status
Completed
Enrollment listed in the registry
72
Sponsor
Duke University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States, Egypt, India
Age range
From 18 Years to 75 Years
Official registry ID
NCT00340379
Official title
Show the full official title

A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Angeles, United States · Alexandria, Egypt · Bangalore, India

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Duke University, a university.

Did this study involve medication?

Yes. The study involved medication, including Ziprasidone, Sertraline and Haloperidol.

Who was this study for?

Listed age limits: 18 years to 75 years.

Want to explore more studies?

Explore studies